Pre-Clinical Development

RXi targets dermal cells with RNA delivery method

RXi targets dermal cells with RNA delivery method

By Nick Taylor

RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.